Veru Overview

  • Year Founded
  • 1971

Year Founded

  • Status
  • Public

  • Employees
  • 20

Employees

  • Stock Symbol
  • VERU

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.94
  • (As of Friday Closing)

Veru General Information

Description

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Contact Information

Formerly Known As
Veru Healthcare, The Female Health Company
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 2916 North Miami Avenue
  • Suite 1000
  • Miami, FL 33137
  • United States
+1 (305)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 2916 North Miami Avenue
  • Suite 1000
  • Miami, FL 33137
  • United States
+1 (305)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Veru Stock Performance

As of 20-Nov-2026, Veru’s stock price is $1.94. Its current market cap is $33.1M with 17.1M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.94 $2.11 $1.93 - $7.33 $33.1M 17.1M 194K -$0.58

Veru Financials Summary

As of 30-Jun-2026, Veru has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 30-Sep-2025 FY 2024 30-Sep-2024 FY 2023 30-Sep-2023
EV 22,306 43,915 97,095 63,149
Revenue 0 0 0 16,297
EBITDA (13,996) (15,529) (34,992) (89,976)
Net Income (13,609) (22,726) (37,801) (93,153)
Total Assets 37,028 29,836 60,419 50,023
Total Debt 2,683 3,117 13,519 14,405
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Veru Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Veru‘s full profile, request access.

Request a free trial

Veru Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic
Drug Discovery
Miami, FL
20 As of 2025

Plymouth Meeting, PA
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Veru Competitors (53)

One of Veru’s 53 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Kura Oncology Formerly VC-backed San Diego, CA
Seres Therapeutics Formerly VC-backed Cambridge, MA
Adicet Bio Formerly VC-backed Boston, MA
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 53 competitors. Get the full list »

Veru Patents

Veru Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260232637-A1 Methods of treating peripheral and coronary artery disease Pending 12-Feb-2025
WO-2026174088-A1 Methods of treating peripheral and coronary artery disease Pending 12-Feb-2025
WO-2026161240-A1 Compositions comprising selective androgen receptor modulator compounds in combination with weight loss drugs Pending 26-Jan-2025
US-20260137648-A1 Compositions comprising selective androgen receptor modulator compounds in combination with weight loss drugs and uses thereof for incremental weight loss and management of adverse side effects of weight loss drugs on body composition Pending 03-Oct-2023
US-12721830-B2 Compositions comprising selective androgen receptor modulator compounds in combination with weight loss drugs and uses thereof for quality weight loss Active 03-Oct-2023 A61K31/277
To view Veru’s complete patent history, request access »

Veru Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Veru Investments & Acquisitions (2)

Veru’s most recent deal was a Corporate Asset Purchase with Camargo Pharmaceutical Services (Formulation rights for solifenacin). The deal was made on 11-Dec-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Camargo Pharmaceutical Services (Formulation rights for solifenacin) 11-Dec-2017 Corporate Asset Purchase Buildings and Property
Aspen Park Pharmaceuticals 31-Oct-2016 Merger/Acquisition Therapeutic Devices
To view Veru’s complete investments and acquisitions history, request access »

Veru ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

38.67 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Veru’s complete esg history, request access »

Veru FAQs

  • When was Veru founded?

    Veru was founded in 1971.

  • Where is Veru headquartered?

    Veru is headquartered in Miami, FL.

  • What is the size of Veru?

    Veru has 20 total employees.

  • What industry is Veru in?

    Veru’s primary industry is Drug Discovery.

  • Is Veru a private or public company?

    Veru is a Public company.

  • What is Veru’s stock symbol?

    The ticker symbol for Veru is VERU.

  • What is the current stock price of Veru?

    As of 20-Nov-2026 the stock price of Veru is $1.94.

  • What is the current market cap of Veru?

    The current market capitalization of Veru is $33.1M.

  • Who are Veru’s competitors?

    Inovio Pharmaceuticals, Kura Oncology, Seres Therapeutics, Adicet Bio, and Immunocore Holdings are some of the 53 competitors of Veru.

  • What is Veru’s annual earnings per share (EPS)?

    Veru’s EPS for 12 months was -$0.58.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process